🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04699279
Recruiting Not applicable

Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)

NCT04699279 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing Medical University
Phase
Not applicable
Started
2021-01-01
Last updated
2024-12-13

Condition(s) studied

Acute Aortic SyndromeAortopathy

Investigational drug(s) / intervention(s)

Rosuvastatin 10mg

Rosuvastatin 10mg: Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.

Study summary

Acute Aortic Syndrome (AAS)/Aortic Aneurysm is a common feature of aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * (1) Patients with aortic dissection/ulceration/intermural hematoma/aortic aneurysm who underwent aortic arch replacement or endoluminal isolation or hybrid therapy; * (2) Paitents without clinically significant hyperlipidemia but with cardiovascular disease risk factors (such as male ≥45 years old, female ≥55 years old, hypertension, diabetes, chronic kidney disease, obesity, low HDL cholesterol, smoking, alcohol consumption, family history of early onset ischemic cardiovascular disease) and no previous use of statins; * (3) Patients are between 18 and 85 years old, male or female; * (4) Agree to participate in the study and sign the informed consent. Exclusion Criteria: * (1) Patients with allergy to statins; * (2) patients with active liver disease; * (3) patients with myopathy; * (4) Lactating women and pregnant women; * (5) Patients with mental diseases, drug and alcohol dependence; * (6) Refuse to participate in the study or sign the informed consent.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong Recruiting
The first affiliated hospital of nanjing medical university Nanjing Jiangsu Recruiting
Affiliated Hospital of Qingdao University Qingdao Shandong Recruiting
West China Hospital of Sichuan University Chengdu Sichuan Recruiting
Beijing Anzhen Hospital Beijing China Recruiting

More Nanjing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04699279 on ClinicalTrials.gov ↗ ← All trials in China